GlaxoSmithKline tests the effectiveness of pre-license medicine using real-world data in Salford
The Salford Lung study is a collaboration between GlaxoSmithKline, NorthWest
EHealth (NWEH), The University of Manchester, Salford Royal NHS Foundation
Trust, Salford Clinical Commissioning Group’s local general practitioners, and local
Its purpose is to test the safety and effectiveness of a new treatment for asthma and Chronic Obstructive Pulmonary Disease, compared with standard medications used for these conditions. The study is a recognised world-first for the comprehensive use of real-world data to evaluate the performance of a pre-license medication.
Sponsored by GlaxoSmithKline (GSK), this research draws on Salford’s e-Health records infrastructure, a clinical information system that provides a single, integrated electronic patient record across primary and secondary care. This ensures patients are closely monitored over the course of the study, yet with minimal intrusion into their everyday lives.
Professor Martin Gibson, Associate Director of Industry at the National Institute for Health Research Comprehensive Research Network, described the Salford Lung Study as “a major advance in the way we do clinical trials.”
Medical Director of GSK’s Respiratory Centre of Excellence, Dr David Leather, said:
“This study is a first in the world, testing a pre-license medicine in a real-world setting and is a tribute to the partnerships we’ve created together, our collaborators and the health care professionals and people of Salford.”